BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...will remain in her role as CBO. Byrnes previously served as SVP of finance at Principia Biopharma...
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...is transitioning to a new role in venture capital. Thomas was most recently CMO at Principia Biopharma...
BioCentury | Dec 12, 2020
Management Tracks

Lum & Dipp’s Biospring rounds out team; plus CHOP’s Smith-Whitley joins GBT and updates from Orphazyme, Kronos, Dewpoint, Enanta and more

...hired Pasit Phiasivongsa as SVP of pharmaceutical development. Phiasivongsa was most recently SVP, technical operations, at Principia Biopharma...
BioCentury | Nov 20, 2020
Finance

SR One’s newfound freedom allows firm to increase focus on company creation

...biotechs, such as CRISPR Therapeutics AG (NASDAQ:CRSP); Principia Biopharma Inc....
BioCentury | Sep 9, 2020
Product Development

Data Bytes: Btk race in MS heats up as Roche enters Phase III

...SAR442168, which Sanofi (Euronext:SAN; NASDAQ:SNY) acquired full rights to through its $3.4 billion takeout of Principia Biopharma Inc....
BioCentury | Aug 28, 2020
Deals

Principia shareholder still wants ‘more favorable outcome’ as filing reveals escalating Sanofi bids ahead of deal

...outcome for Principia,” wrote Lampert. “We are open to discussing our views with any interested parties.”Principia Biopharma Inc....
BioCentury | Aug 17, 2020
Deals

Via $3.4B Principia takeout, Sanofi can explore potential of Btk inhibitor beyond MS

...could yield further candidates and effectively buys out its own milestone and royalty obligations to Principia Biopharma Inc....
...for an overview of other therapies in development for MS. TARGETSBtk – Bruton’s tyrosine kinase Paul Bonanos PRN2246, SAR442168 Sanofi Principia Biopharma Inc. Bruton's...
BioCentury | Apr 24, 2020
Product Development

Sanofi sets MS submission goals for Principia-partnered Btk inhibitor, details Phase II data

...NR-SPMS are on track to begin mid-year. Sanofi licensed the Btk inhibitor in 2017 from Principia Biopharma Inc....
...a market cap of $2.1 billion. Targets Btk - Bruton’s tyrosine kinase Sandi Wong, Assistant Editor PRN2246, SAR442168 Sanofi Principia Biopharma Inc. Bruton's...
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...assessed by MRI. Sanofi has global development and commercial rights to the BTK inhibitor from Principia Biopharma Inc....
...BTK - Bruton’s tyrosine kinase BioCentury Staff PRN2246, SAR442168 Flanders Institute for Biotechnology (VIB) Ghent University NIH University of Texas at Austin Sanofi Principia Biopharma Inc. Coronavirus...
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

...build on its success in multiple sclerosis with BTK inhibitor SAR442168, which is licensed from Principia Biopharma Inc....
Items per page:
1 - 10 of 49
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...will remain in her role as CBO. Byrnes previously served as SVP of finance at Principia Biopharma...
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...is transitioning to a new role in venture capital. Thomas was most recently CMO at Principia Biopharma...
BioCentury | Dec 12, 2020
Management Tracks

Lum & Dipp’s Biospring rounds out team; plus CHOP’s Smith-Whitley joins GBT and updates from Orphazyme, Kronos, Dewpoint, Enanta and more

...hired Pasit Phiasivongsa as SVP of pharmaceutical development. Phiasivongsa was most recently SVP, technical operations, at Principia Biopharma...
BioCentury | Nov 20, 2020
Finance

SR One’s newfound freedom allows firm to increase focus on company creation

...biotechs, such as CRISPR Therapeutics AG (NASDAQ:CRSP); Principia Biopharma Inc....
BioCentury | Sep 9, 2020
Product Development

Data Bytes: Btk race in MS heats up as Roche enters Phase III

...SAR442168, which Sanofi (Euronext:SAN; NASDAQ:SNY) acquired full rights to through its $3.4 billion takeout of Principia Biopharma Inc....
BioCentury | Aug 28, 2020
Deals

Principia shareholder still wants ‘more favorable outcome’ as filing reveals escalating Sanofi bids ahead of deal

...outcome for Principia,” wrote Lampert. “We are open to discussing our views with any interested parties.”Principia Biopharma Inc....
BioCentury | Aug 17, 2020
Deals

Via $3.4B Principia takeout, Sanofi can explore potential of Btk inhibitor beyond MS

...could yield further candidates and effectively buys out its own milestone and royalty obligations to Principia Biopharma Inc....
...for an overview of other therapies in development for MS. TARGETSBtk – Bruton’s tyrosine kinase Paul Bonanos PRN2246, SAR442168 Sanofi Principia Biopharma Inc. Bruton's...
BioCentury | Apr 24, 2020
Product Development

Sanofi sets MS submission goals for Principia-partnered Btk inhibitor, details Phase II data

...NR-SPMS are on track to begin mid-year. Sanofi licensed the Btk inhibitor in 2017 from Principia Biopharma Inc....
...a market cap of $2.1 billion. Targets Btk - Bruton’s tyrosine kinase Sandi Wong, Assistant Editor PRN2246, SAR442168 Sanofi Principia Biopharma Inc. Bruton's...
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...assessed by MRI. Sanofi has global development and commercial rights to the BTK inhibitor from Principia Biopharma Inc....
...BTK - Bruton’s tyrosine kinase BioCentury Staff PRN2246, SAR442168 Flanders Institute for Biotechnology (VIB) Ghent University NIH University of Texas at Austin Sanofi Principia Biopharma Inc. Coronavirus...
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

...build on its success in multiple sclerosis with BTK inhibitor SAR442168, which is licensed from Principia Biopharma Inc....
Items per page:
1 - 10 of 49